CABA · Cabaletta Bio, Inc.

The thesis

Cabaletta Bio's rese-cel autoimmune cell-therapy story is unchanged on the facts while the shares keep falling: they closed at $1.46 on 27 October 2026, 64.9% below the 52-week high of $4.15. The third-quarter report expected around 12 November 2026 and the fourth-quarter 2026 start of a second registrational cohort settle whether the selloff is overdone.

Rese-cel is Cabaletta's CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for autoimmune disease. The 13 August 2026 company update placed registrational RESET-Myositis data in mid-2027 and a possible biologics license application in the second half of 2027. Searches of company filings and news found no Cabaletta announcement dated after 1 September 2026.

The narrative is maturing: the story is well known, no new disclosure has appeared since 1 September 2026, and the adjusted close fell from $1.62 on 14 October 2026 to $1.46 on 27 October 2026. The three-month price change is -46.5%. The 14-day relative strength index (RSI, a 0-100 momentum gauge where readings under 30 are called oversold) is 27.1.

Bullish and bearish views on Cabaletta Bio, Inc.

The bull case on Cabaletta Bio, Inc. (CABA), in brief: Early responses support registrational testing. The bear case: Shares keep falling without news.

Bull case

• Early responses support registrational testing. The 13 August 2026 company update said 8 of 10 evaluable adults presented at the June 2026 European Alliance of Associations for Rheumatology (EULAR) congress would have met the registrational endpoint. The sample is ten patients, too small to carry a conclusion on its own.
• Broader data set at EULAR. The company's 3 June 2026 8-K reported data on 52 evaluable patients across myositis, lupus and systemic sclerosis. In dermatomyositis, 5 of 6 patients (83%) reached an immunomodulator-free response at 16 weeks.
• Cash covers the near-term plan. Cabaletta reported $225.1 million in cash, cash equivalents and short-term investments at 30 June 2026, against $133.6 million at 31 December 2025, with runway into mid-2027 (Q2 2026 results release, 13 August 2026).
• Analyst targets sit well above the shares. H.C. Wainwright reiterated Buy with a $16 target on 1 September 2026 (Benzinga). Wells Fargo kept Equal-Weight and cut its target to $3 on 14 August 2026 (Benzinga), still above the $1.46 close.

Bear case

• Shares keep falling without news. The adjusted close moved from $2.55 on 18 September 2026 to $1.89 on 1 October 2026, $1.62 on 14 October 2026 and $1.46 on 27 October 2026. Company releases and news searches show no disclosure after 1 September 2026 that explains it.
• Funding and data dates coincide. Runway reaches only mid-2027, the same period as registrational myositis results. Cabaletta priced a $150 million underwritten offering on 4 May 2026 and has an active at-the-market stock-sale program, so a further raise at a lower price remains possible before the data arrive.
• No clinical data arrives soon. The next company-controlled milestone is the fourth-quarter 2026 start of the roughly 25-patient RESET-SSc-ILD (systemic sclerosis with interstitial lung disease) cohort. A miss would push a second registrational program past year-end.
• Prior levels are now overhead. The 52-week high is $4.15. The $1.62 close of 14 October 2026 and the $1.89 close of 1 October 2026 both sit above the shares.

Price setup

The last adjusted close was $1.46 on 27 October 2026. That is 64.9% below the 52-week high of $4.15, and the three-month change is -46.5%. The 14-day RSI of 27.1 remains in oversold territory.

The close is one cent above $1.45, the invalidation level in the previous note, which had not been breached as of 27 October 2026. Selling has been steady for six weeks with no company disclosure behind it. Analyst targets of $3 (Wells Fargo) and $16 (H.C. Wainwright) are both far above the shares.

Crowding evidence is limited to the quarterly report ahead and the at-the-market program. Heavy retail attention is not evidenced in the news flow.

Catalysts, next 30 days

• ~12 November 2026, est.: third-quarter 2026 results and business update. An earnings calendar site lists 10 November 2026, unconfirmed by the company; the second-quarter report came on 13 August 2026. The report shows cash burn against the $225.1 million June balance, the runway wording and whether mid-2027 myositis guidance holds.
• Fourth quarter 2026, est.: start of the RESET-SSc-ILD registrational cohort. A start would be the only company-controlled milestone before 2027.
• Second half of 2026, guided: longer-term preconditioning-free data from the lowest-dose RESET-PV and RESET-SLE cohorts, per earlier company guidance reported in a 2026 results summary. No date has been given.

What would change the view

The case breaks if the company guides RESET-Myositis data beyond mid-2027, if the SSc-ILD cohort has not started by 31 December 2026, or if the third-quarter report shows a runway shorter than mid-2027. A new equity offering priced below the $1.46 close of 27 October 2026 would also weaken it. On price, a daily close below $1.45 would extend the decline through the level the previous note named.

A third-quarter report that confirms mid-2027 guidance and an on-schedule cohort start would support the view that the selloff has run ahead of the facts.

What it trades with

Cabaletta trades with other clinical-stage cell-therapy and autoimmune biotechs and with small-cap biotech funding conditions. Its moves since mid-September have not been explained by company news, so sector sentiment and financing worries are the likely drivers. Peer autoimmune CAR-T data or competing programs could move the shares independently of Cabaletta's own results.